Visceral obesity, metabolic syndrome, insulin resistance and cancer
- S. L. Doyle; C. L. Donohoe; J. Lysaght; J. V. Reynolds Visceral obesity, metabolic syndrome, insulin resistance and cancer Proc Nutr Soc
Insulin Resistance & Diabetes
Top single nucleotide polymorphisms affecting carbohydrate metabolism in metabolic syndrome: From the LIPGENE study
- J. Delgado-Lista; P. Perez-Martinez; S. Juan; A. Garcia-Rios; A. I. Perez-Caballero; J. A. Lovegrove; C. A. Drevon; C. Defoort; E. E. Blaak; A. Dembinska-Kieć; U. Riśrus; E. Herruzo-Gomez; A. Camargo; J. M. Ordovas; H. Roche; J. Lopez-Miranda Top single nucleotide polymorphisms affecting carbohydrate metabolism in metabolic syndrome: From the LIPGENE study Journal of Clinical Endocrinology and Metabolism
Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein beta up-regulation
- L. A. Powell; P. Crowe; C. Kankara; J. McPeake; D. R. McCance; I. S. Young; E. R. Trimble; A. McGinty Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein beta up-regulation Clinical science
Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice
- W. D. Porter; P. R. Flatt; C. Hölscher; V. A. Gault Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice International Journal of Obesity
Liraglutide: another reason to target prediabetes?
- C. F. Murphy; N. G. Docherty; C. W. le Roux Liraglutide: another reason to target prediabetes? Oncotarget
Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial
- D. Papamargaritis; W. Al-Najim; J. Lim; J. Crane; M. Lean; C. le Roux; B. McGowan; D. O'Shea; D. Webb; J. Wilding; M. J. Davies Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial BMJ Open
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
- R. J. McCrimmon; A. M. Catarig; J. P. Frias; N. L. Lausvig; C. W. le Roux; D. Thielke; I. Lingvay Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial Diabetologia
Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial
- A. D. Miras; B. Pérez-Pevida; M. Aldhwayan; A. Kamocka; E. R. McGlone; W. Al-Najim; H. Chahal; R. L. Batterham; B. McGowan; O. Khan; V. Greener; A. R. Ahmed; A. Petrie; S. Scholtz; S. R. Bloom; T. M. Tan Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial Lancet Diabetes Endocrinol
Regulating the effects of GPR21, a novel target for type 2 diabetes
- S. Leonard; G. K. Kinsella; E. Benetti; J. B. Findlay Regulating the effects of GPR21, a novel target for type 2 diabetes Scientific reports